ASCO GU 2023 Conference Coverage

 

ASCO GU 2023 Conference Coverage
O

ASCO GU 2023 Real-World Evidence From Four High-Volume Institutions: Characteristics of Long-Term Responder Patients Treated With Androgen-Receptor Signaling Inhibitors as a 1L Treatment for mCRPC

By ASCO GU 2023 Conference Coverage FEATURING Orazio Caffo
By ASCO GU 2023 Conference Coverage FEATURING Orazio Caffo
31 views
February 28, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Videos
07:52
ASCO GU 2023 Conference Coverage

Independent Biomarkers Predictive of Outcomes With Enfortumab Vedoti…

Feat. T. Jindal
06:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 DEAR Study: Real-World Use of Darolutamide, Enzalutamid…

Feat. D. George
12:39
ASCO GU 2023 Conference Coverage

Efficacy and Safety of Darolutamide in Combination With ADT and Doce…

Feat. C. Sternberg
08:18
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Effectiveness of Darolutamide in mCRPC

Feat. A. Liang
05:39
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Analysis of the UNITE Study: Biomarkers of Response to …

Feat. T. Jindal
11:07
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Innovative and Pragmatic Methods to Study BCG-Unrespons…

Feat. J. Gore
07:09
ASCO GU 2023 Conference Coverage

ASCO GU 2023 HER2 Expression in Urothelial Carcinoma

Feat. V. Koshkin
07:23
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Response & Outcomes of Maintenance Avelumab After P…

Feat. P. Grivas, D. Bakaloudi
10:44
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Additional Results From the Randomized Phase 2 CheckMat…

Feat. R. Pachynski
07:06
ASCO GU 2023 Conference Coverage

ASCO GU 2023 JAVELIN Bladder 100 Trial: Avelumab 1L Maintenance for …

Feat. K. Sridhar
05:40
ASCO GU 2023 Conference Coverage

ASCO GU 2023 International Phase 3 Randomised Controlled PACE-A Tria…

Feat. N. van As
08:32
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Assessment of AR-LBD Mutations in mCRPC

Feat. E. Antonarakis
07:36
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Assessment of Clavien-Dindo Classification in Patients …

Feat. K. Runcie
05:31
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase I/II AlphaBet Trial: Evaluating the Combination o…

Feat. A. Azad
04:34
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase I/II LuCAB Trial: Evaluating Cabazitaxel in Combi…

Feat. A. Azad
05:20
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Efficacy of Systemic Therapy Following [177Lu]Lu-PSMA i…

Feat. A. Azad
03:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Adjuvant Therapies in Renal Cell Carcinoma: Are New Dat…

Feat. M. Zibelman
05:47
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial: …

Feat. T. Powles
07:03
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Evidence From Four High-Volume Institutions:…

Feat. O. Caffo
10:24
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Data from an Italian Multicenter Observation…

Feat. O. Caffo
07:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 First Analysis From an Italian Multicenter Observationa…

Feat. O. Caffo
12:48
ASCO GU 2023 Conference Coverage

Cost-Effectiveness Analysis of Seven Treatment Regimens in mHSPC: A …

Feat. M. Kohli
07:53
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase 3 IMvigor130 Study: Final OS Analysis of Atezo Mo…

Feat. A. Bamias
13:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Interim Analysis of the Prospective Phase II COTRIMS Tr…

Feat. A. Heidenreich
09:47
ASCO GU 2023 Conference Coverage

FDA Announcement Based on the MAGNITUDE Trial: Niraparib With Abirat…

Feat. E. Efstathiou
01:46
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blind Phase 3 KEYNOTE-921 Study: Pemb…

Feat. D. Petrylak
08:45
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Machine-Learning to Predict Utility of ctDNA for Somati…

Feat. C. Herberts
04:49
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Updated Outcomes in TROPHY-U-01 Cohort 1-A Phase 2 Stud…

Feat. S. Tagawa
05:48
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blinded Phase II Study of Keto HC and…

Feat. S. Tagawa
14:09
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Exposure Toxicity and Response Relationship of Cabozant…

Feat. Y. Vano
04:20
ASCO GU 2023 Conference Coverage

ASCO GU 2023 CaboPoint Phase 2 Study: Cabozantinib After Checkpoint …

Feat. L. Albiges
05:32
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Cell-Free utDNA to Detect MRD Prior to Repeat-Transuret…

Feat. K. Rose
14:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Pro…

Feat. A. D'Amico
12:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Novel Guidelines for PSMA PET Staging of Prostate Cance…

Feat. D. Nanus
12:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Sequential Enfortumab Vedotin After Platinum-Based Chem…

Feat. P. Cen
08:15
ASCO GU 2023 Conference Coverage

ASCO GU 2023 3-Year Follow-Up From The Phase 3 CheckMate 9ER Trial: …

Feat. M. Burotto
15:17
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Systemic Therapy for Recurrent Metastatic RCC: Beyond S…

Feat. T. Zhang
02:42
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day Three Highlights With Resident Jindal and Dr. Park

Feat. T. Jindal, C. Park
22:25
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Prostate and Bladder Updates With Dr. Jones and Dr. Park

Feat. R. Jones, C. Park
09:22
ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Grivas Discuss TROPHY-U-01 and EV-201…

Feat. P. Grivas, C. Park
08:13
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Plimack and Dr. Park Discuss Over-Treating in Muscl…

Feat. E. Plimack, C. Park
08:59
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Treatment Outcomes With New Targeted Agents in Advanced…

Feat. V. Koshkin, C. Park
06:04
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase II Study Rucaparib Monotherapy in Pts With nmHSPC…

Feat. K. Sahu, C. Park
06:34
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Flaig and Dr. Park Discuss Updates in Prostate and …

Feat. T. Flaig, C. Park
05:18
ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Miron and Dr. Park Discuss Kidney and Bladder Upda…

Feat. B. Miron, C. Park
06:19
ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Gupta Discuss the BLASST-1 Study

Feat. S. Gupta, C. Park
09:12
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Longitudinal Detection of ctDNA in Patients With Advanc…

Feat. A. Basu, C. Park
03:08
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day Two Highlights With Dr. Talukder and Dr. Park

Feat. R. Talukder, C. Park
10:32
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Rettig and Dr. Park Discuss Prostate Cancer Updates

Feat. M. Rettig, C. Park
05:57
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Comparison of ctDNA Between African-American and Caucas…

Feat. A. Jang, C. Park
10:01
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Bladder Cancer Highlights With Dr. Sonpavde and Dr. Park

Feat. G. Sonpavde, C. Park
01:53
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day One Highlights With Dr. Zakharia

Feat. Y. Zakharia